This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Edwards Lifesciences (EW)

Tipranks - Tipranks - Sat Jun 13, 10:04AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Jazz Pharmaceuticals (JAZZ) and Edwards Lifesciences (EW) with bullish sentiments.

Introducing TipRanks MCP for Agents

Jazz Pharmaceuticals (JAZZ)

In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Jazz Pharmaceuticals, with a price target of $275.00. The company’s shares closed last Friday at $230.81.

According to TipRanks.com, Thome is a 5-star analyst with an average return of 20.6% and a 54.9% success rate. Thome covers the Healthcare sector, focusing on stocks such as MapLight Therapeutics, Inc., Amylyx Pharmaceuticals Inc, and Rapport Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jazz Pharmaceuticals with a $262.29 average price target, implying an 11.4% upside from current levels. In a report issued on June 9, Truist Financial also initiated coverage with a Buy rating on the stock with a $256.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Edwards Lifesciences (EW)

In a report released today, Brandon Vazquez from William Blair maintained a Buy rating on Edwards Lifesciences. The company’s shares closed last Friday at $83.65.

According to TipRanks.com, Vazquez ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -7.3% and a 35.2% success rate. Vazquez covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Irhythm Technologies, and Elanco Animal Health. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Edwards Lifesciences with a $98.27 average price target, representing a 13.6% upside. In a report issued on June 9, Bank of America Securities also maintained a Buy rating on the stock with a $100.00 price target.

Read More on JAZZ:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).